Browse drugs

…oxygenation strategies remain limited for clinical translation. NanO 2 (NuvOx Pharma), a novel perfluorocarbon-based oxygen therapeuti…

… tumors and tumor draining lymph nodes to unveil the effects of APMV-4 ISV on host immune responses. Ex vivo splenocyte stimulation wa…

…ent strategies are required to achieve durable tumor rejection. Odronextamab, a CD20xCD3 bispecific antibody, has been approved in the EU fo…

…ing tumor acidity and reshaping the metabolic microenvironment, pramlintide may enhance immune cell trafficking and function, supporting it…

…lick AC, Jiang J, Avila A, … Margolin K. Combined nivolumab and ipilimumab in melanoma metastatic to the brain. The New England Journal of…

…tial treatment strategy for patients with STK11-mutated tumors. TNG260 in combination with pembrolizumab is currently being evaluated …

…ulatory cytokines, intensifying the anti-tumor response.Methods Trastuzumab emtansine (T-DM1, KADCYLA) served as the lead ADC. To increase the drug p…

…ti-PD-1 or anti-PD-L1 antibodies) plus concurrent chemotherapy (cisplatin or carboplatin) is now part of the standard of care for non-sma…

…the metabolic and functional suppression observed with existing OxPhos inhibitors. In vivo, NDUFA7 knockdown MC38 tumors show signific…

…nt on the same cell.Conclusions Together, our data suggest that Daiad-2/15 could potentiate the systemic delivery of a highly potent immun…

…nto microfluidic devices, and treated with GFP-LNPs (10 µg/ml), cGASΔN-LNPs (1 and 10 µg/ml), or αPD-L1 monoclonal antibody (300 µg/ml). GF…

…t 48 hr. For low-dose RPT, mice were administered 225Ac-A2DM or 177Lu-A2DM, and tumors collected at days 4, 7 and/or 14. Tissues were form…